Equities Analysts Set Expectations for Juno Therapeutics, Inc.’s Q3 2017 Earnings (JUNO)

Juno Therapeutics, Inc. (NASDAQ:JUNO) – Equities researchers at Wedbush raised their Q3 2017 earnings estimates for shares of Juno Therapeutics in a note issued to investors on Tuesday. Wedbush analyst D. Nierengarten now anticipates that the biopharmaceutical company will post earnings of ($0.96) per share for the quarter, up from their prior estimate of ($1.05). Wedbush currently has a “Outperform” rating and a $42.00 price target on the stock. Wedbush also issued estimates for Juno Therapeutics’ Q4 2017 earnings at ($0.98) EPS, FY2017 earnings at ($3.69) EPS, Q1 2018 earnings at ($1.00) EPS, Q2 2018 earnings at ($0.97) EPS, Q3 2018 earnings at ($0.99) EPS, Q4 2018 earnings at ($1.09) EPS, FY2018 earnings at ($4.06) EPS, FY2019 earnings at ($4.38) EPS, FY2020 earnings at ($4.08) EPS and FY2021 earnings at ($3.30) EPS.

Juno Therapeutics (NASDAQ:JUNO) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.72) by $0.24. The company had revenue of $21.30 million during the quarter, compared to the consensus estimate of $15.59 million. Juno Therapeutics had a negative net margin of 354.36% and a negative return on equity of 27.10%. The business’s revenue was down 22.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.64) EPS. WARNING: “Equities Analysts Set Expectations for Juno Therapeutics, Inc.’s Q3 2017 Earnings (JUNO)” was originally published by TrueBlueTribune and is the property of of TrueBlueTribune. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.truebluetribune.com/2017/09/08/equities-analysts-set-expectations-for-juno-therapeutics-inc-s-q3-2017-earnings-juno.html.

A number of other analysts have also commented on the company. Vetr raised Juno Therapeutics to a “buy” rating in a research note on Tuesday, May 23rd. BidaskClub raised Juno Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, June 27th. Morgan Stanley dropped their price target on Juno Therapeutics from $27.00 to $26.00 and set an “equal weight” rating for the company in a research note on Monday, May 8th. FBR & Co reaffirmed a “hold” rating on shares of Juno Therapeutics in a research note on Thursday, May 18th. Finally, BTIG Research lowered Juno Therapeutics from a “neutral” rating to a “sell” rating and raised their price target for the stock from $22.60 to $23.73 in a research note on Thursday, June 8th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $31.86.

Shares of Juno Therapeutics (NASDAQ JUNO) opened at 41.27 on Thursday. The company’s market cap is $4.33 billion. Juno Therapeutics has a 1-year low of $17.52 and a 1-year high of $43.10. The stock has a 50 day moving average of $29.97 and a 200 day moving average of $25.69. Juno Therapeutics also saw unusually large options trading on Tuesday. Investors bought 6,838 put options on the company. This is an increase of approximately 977% compared to the average daily volume of 635 put options.

In other news, EVP Robert Azelby sold 12,869 shares of the firm’s stock in a transaction on Tuesday, August 29th. The stock was sold at an average price of $39.95, for a total transaction of $514,116.55. Following the completion of the transaction, the executive vice president now directly owns 50,289 shares in the company, valued at $2,009,045.55. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Douglas K. Bratton sold 8,000,000 shares of the firm’s stock in a transaction on Thursday, July 13th. The shares were sold at an average price of $27.00, for a total value of $216,000,000.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 8,066,369 shares of company stock valued at $218,108,557. 15.26% of the stock is owned by corporate insiders.

Institutional investors have recently modified their holdings of the stock. Karp Capital Management Corp bought a new position in shares of Juno Therapeutics during the first quarter valued at $562,000. UBS Asset Management Americas Inc. increased its position in shares of Juno Therapeutics by 76.4% in the first quarter. UBS Asset Management Americas Inc. now owns 29,900 shares of the biopharmaceutical company’s stock valued at $663,000 after buying an additional 12,947 shares during the last quarter. Pictet Asset Management Ltd. increased its position in shares of Juno Therapeutics by 14.0% in the first quarter. Pictet Asset Management Ltd. now owns 384,745 shares of the biopharmaceutical company’s stock valued at $8,538,000 after buying an additional 47,267 shares during the last quarter. BNP Paribas Arbitrage SA increased its position in shares of Juno Therapeutics by 40.1% in the first quarter. BNP Paribas Arbitrage SA now owns 28,481 shares of the biopharmaceutical company’s stock valued at $632,000 after buying an additional 8,150 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of Juno Therapeutics by 2.8% in the first quarter. Bank of New York Mellon Corp now owns 262,801 shares of the biopharmaceutical company’s stock valued at $5,832,000 after buying an additional 7,165 shares during the last quarter. Hedge funds and other institutional investors own 70.76% of the company’s stock.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Earnings History and Estimates for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

3 × 2 =